INSIGHTS ON CELL & GENE THERAPY DISCOVERY

• Analysis Of Cancer Spheroids Through High-Throughput Screening Assays

  In recent years, tumor-derived spheroids have been utilized to optimize cancer therapeutics for ovarian and hepatocellular carcinoma. However, there are some challenges to using spheroids for drug screening. Here we outline different kinds of high-throughput screening (HTS) assays that can be performed on cancer spheroids to assess drug response. We also provide some useful guidelines for handling spheroids and acquiring data to get the most meaningful results.

• AI(d) To Increase Drug Discovery Productivity And Optimize SPR Data Interpretation

  The need to increase efficiency and productivity has led scientists to develop a machine learning solution that can optimize the way that developers analyze and characterize their early drug candidates.

• A Primer On Cancer Immunotherapy Part 1: Goals And Major Approaches

  This post provides an introduction to cancer immunotherapy, exploring its immunological basis and the fundamental principles guiding the development of new treatments.

• Continuing The Conversation: The Future Of Reimbursement For Cell And Gene Therapies

  Cell and gene therapies were expected to pose significant payer challenges however, several high-cost cell and gene therapies have achieved rapid and broad reimbursement to date across major payer bodies.

• From Cells To Organs – The Organoid Stepping-Stone

  In recent years, biomedical research has pushed the limits of 2D cell culture to develop more advanced models for studying developmental biology and disease-modelling and also to identify more efficient tissue-replacement therapies. Of particular interest in these areas is tailored 3D cell culture approaches that give rise to organ-like structures known as “organoids”.

• Why Institutions Should Consider An Externally Administered IBC

  Read in the available blog how clinical trials for gene therapy are booming, especially in the fields of oncology, infectious diseases, rare diseases, and regenerative medicine.

• Understanding The Current And Future States Of Cell And Gene Therapy Research

  In recent years, the gene therapy field has experienced booming growth. This white paper focuses on gene therapy uses in oncology and discusses operations and infrastructure at a cellular immunotherapy program at a National Cancer Institute (NCI)-designated comprehensive cancer center.

• Gene Therapies In Hemophilia

  Potentially curative gene therapies for hemophilia are getting closer to market, representing a transformation in care for many thousands of patients. Download the available white paper to find out more.

• Transcript Regulation Of 18 ADME Genes By Prototypical Inducers In Human Hepatocytes

  The importance of measuring mRNA to assess induction potential is paramount. The fundamental change from measuring enzyme activities to transcripts will have profound implications for workflow in studying drug–drug interactions (DDI) involving induction. In this study, we used Invitrogen™ QuantiGene™ Plex Assays to simultaneously measure 18 ADME transcripts and two controls. The data shows the power of the QuantiGene Plex Assay to generate profiles of transcript levels from a single concentration or a concentration response curve of an inducer in a multiplex format.

• Determination Of Gene Signatures To Subgroup Melanoma Patients Using Novel Branched DNA Hybridization Assays

  Gene expression signatures have been successfully employed to distinguish cancer subtypes in many tumor types including melanoma; however, melanin content of later-stage melanomas and age of stored formalin-fixed, paraffinembedded (FFPE) samples can make gene expression analysis difficult. Here we describe two gene expression technologies to validate microarray data, that work either directly on melanoma tissue lysates using the Invitrogen™ QuantiGene™ Plex Assay, or by in situ hybridization (ISH) using the Invitrogen™ ViewRNA™ ISH Tissue Assay, which uses FFPE tissue sections.